Cancer immunotherapies that inhibit negative immune feedback, such as those targeting programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PDL1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4), have proven efficacious against several tumor types [34, 35]. Here, CD274 is linked to neoplasm.